Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Dow
Teva
AstraZeneca
McKinsey
Julphar
Baxter
Harvard Business School
Covington

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022023

« Back to Dashboard

NDA 022023 describes EMEND, which is a drug marketed by Merck, Msd Merck Co, and Merck And Co Inc, and is included in three NDAs. It is available from three suppliers. There are four patents protecting this drug and four Paragraph IV challenges. Additional details are available on the EMEND profile page.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
Summary for 022023
Tradename:EMEND
Applicant:Merck And Co Inc
Ingredient:fosaprepitant dimeglumine
Patents:2
Suppliers and Packaging for NDA: 022023
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023 NDA Merck Sharp & Dohme Corp. 0006-3061 N 0006-3061-00
EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023 NDA Merck Sharp & Dohme Corp. 0006-3941 N 0006-3941-32

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INTRAVENOUSStrengthEQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jan 25, 2008TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 4, 2019Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrengthEQ 150MG BASE/VIAL
Approval Date:Nov 12, 2010TE:APRLD:Yes
Regulatory Exclusivity Expiration:Feb 1, 2019
Regulatory Exclusivity Use:SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
Patent:➤ Sign UpPatent Expiration:Sep 4, 2019Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 022023

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Sign Up ➤ Sign Up
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Sign Up ➤ Sign Up
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Sign Up ➤ Sign Up
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Moodys
Daiichi Sankyo
Colorcon
Boehringer Ingelheim
Dow
Deloitte
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.